摘要
目的:观察扶正化瘀片联合恩替卡韦治疗乙型病毒性肝炎(简称乙肝)肝硬化患者的效果。方法:选取2022年7月至2023年7月该院收治的100例乙肝肝硬化患者进行前瞻性研究,按照随机数字表法将其分为对照组和观察组各50例。两组均给予常规治疗,在此基础上,对照组予以恩替卡韦治疗,观察组在对照组基础上联合扶正化瘀片治疗。比较两组临床疗效,治疗前后肝功能指标[天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、总胆红素(TBIL)、凝血酶原活动度(PTA)]、肝纤维化指标[透明质酸(HA)、Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原蛋白(Ⅳ-C)、层粘连蛋白(LN)]、肝硬度值、T细胞亚群指标(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))水平,以及不良反应发生率。结果:观察组治疗总有效率为96.00%(48/50),高于对照组的84.00%(42/50),差异有统计学意义(P<0.05);治疗后,两组ALT、AST、TBIL水平均低于治疗前,且观察组低于对照组,两组PTA水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);治疗后,两组HA、LN、Ⅳ-C、PCⅢ水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组肝硬度值均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均高于治疗前,且观察组高于对照组,两组CD8^(+)水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:扶正化瘀片联合恩替卡韦治疗乙肝肝硬化患者可提高治疗总有效率,改善肝功能指标和T细胞亚群指标水平,降低肝纤维化指标水平和肝硬度值,效果优于单纯恩替卡韦治疗。
Objective:To observe effects of Fuzheng Huayu tablets combined with Entecavir in treatment of patients with hepatitis B cirrhosis.Methods:A prospective study was conducted on 100 patients with hepatitis B cirrhosis admitted to the hospital from July 2022 to July 2023.According to the random number table method,they were divided into control group and observation group,50 cases in each group.Both groups were given routine treatment.On this basis,the control group was treated with Entecavir,while the observation group was treated with Fuzheng Huayu tablets on the basis of that of the control group.The clinical efficacy,the levels of liver function indexes[aspartate aminotransferase(AST),alanine aminotransferase(ALT),total bilirubin(TBIL),prothrombin activity(PTA)],liver fibrosis indexes[hyaluronic acid(HA),type III procollagen(PCIII),type IV collagen(IV-C),laminin(LN)],liver hardness value and T cell subsets indexes(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+))levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 96.00%(48/50),which was higher than 84.00%(42/50)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of ALT,AST and TBIL in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;the PTA levels of the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of HA,LN,IV-C and PCIII in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the liver stiffness values of the two groups were lower than those before the treatment,that in the observation group was lower than that in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the two groups were higher than those before the treatment,and those in the observation group were higher than those in the control group;the levels of CD8^(+)in the two groups were lower than those before the treatment,and that in the observation group was lower than that in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Fuzheng Huayu tablets combined with Entecavir in the treatment of the patients with hepatitis B cirrhosis can improve the total effective rate of treatment,improve the levels of liver function indexes and T cell subsets indexes,and reduce the levels of liver fibrosis indexes and liver hardness value.Moreover,it is superior to simple Entecavir treatment.
作者
柳淼
LIU Miao(1^(st)Ward of Digestive Department of Jiaozuo People’s Hospital,Jiaozuo 454002 Henan)
出处
《中国民康医学》
2025年第1期126-129,共4页
Medical Journal of Chinese People’s Health
